Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas F Scott

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Movement Disorders Clinical Practice|May 13, 2021
Self-Reported Barriers to Exercise and Factors Impacting Participation in Exercise in Patients with Parkinson's DiseasePrarthana Prakash, Thomas F Scott, Susan M Baser, et al.
Multiple Sclerosis and Related Disorders|February 15, 2022
Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAINScott D Newsome, Thomas F Scott, Douglas L Arnold, et al.
Neuromodulation : Journal of the International Neuromodulation Society|March 29, 2016
Treatment of Neuropathic Pain and Functional Limitations Associated With Multiple Sclerosis Using an MRI-Compatible Spinal Cord Stimulator: A Case Report With Two Year Follow-Up and Literature ReviewDavid A Provenzano, Joseph R Williams, Gaye Jarzabek, et al.
Acta Neurologica Scandinavica|July 18, 2019
Multiple sclerosis relapses contribute to long-term disabilityThomas F Scott, Daniel Diehl, Wisam Elmalik, et al.
The American Journal of the Medical Sciences|February 1, 2013
Spinal cord neurosarcoidosisMimi Sohn, Daniel A Culver, Marc A Judson, et al.
Therapeutic Advances in Neurological Disorders|January 25, 2021
Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetateThomas F Scott, Ray Su, Kuangnan Xiong, et al.
International Journal of MS Care|July 2, 2020
Outcomes in a Modern Cohort of Treated Patients with Multiple Sclerosis from Diagnosis Up to 15 YearsThomas F Scott, Troy Desai, Chris Hackett, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosisThomas F Scott, Bernd C Kieseier, Scott D Newsome, et al.
BMC Neurology|December 21, 2011
Preliminary study: treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2+ and decreased levels of IL23R+ CD4+ T - Lymphocytes in multiple sclerosisJennifer M Kress-Bennett, Garth D Ehrlich, Ashley Bruno, et al.
Therapeutic Advances in Neurological Disorders|September 6, 2018
Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAINScott D Newsome, Thomas F Scott, Douglas L Arnold, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Movement Disorders Clinical Practice|May 13, 2021
Self-Reported Barriers to Exercise and Factors Impacting Participation in Exercise in Patients with Parkinson's DiseasePrarthana Prakash, Thomas F Scott, Susan M Baser, et al.
Multiple Sclerosis and Related Disorders|February 15, 2022
Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAINScott D Newsome, Thomas F Scott, Douglas L Arnold, et al.
Neuromodulation : Journal of the International Neuromodulation Society|March 29, 2016
Treatment of Neuropathic Pain and Functional Limitations Associated With Multiple Sclerosis Using an MRI-Compatible Spinal Cord Stimulator: A Case Report With Two Year Follow-Up and Literature ReviewDavid A Provenzano, Joseph R Williams, Gaye Jarzabek, et al.
Acta Neurologica Scandinavica|July 18, 2019
Multiple sclerosis relapses contribute to long-term disabilityThomas F Scott, Daniel Diehl, Wisam Elmalik, et al.
The American Journal of the Medical Sciences|February 1, 2013
Spinal cord neurosarcoidosisMimi Sohn, Daniel A Culver, Marc A Judson, et al.
Therapeutic Advances in Neurological Disorders|January 25, 2021
Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetateThomas F Scott, Ray Su, Kuangnan Xiong, et al.
International Journal of MS Care|July 2, 2020
Outcomes in a Modern Cohort of Treated Patients with Multiple Sclerosis from Diagnosis Up to 15 YearsThomas F Scott, Troy Desai, Chris Hackett, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosisThomas F Scott, Bernd C Kieseier, Scott D Newsome, et al.
BMC Neurology|December 21, 2011
Preliminary study: treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2+ and decreased levels of IL23R+ CD4+ T - Lymphocytes in multiple sclerosisJennifer M Kress-Bennett, Garth D Ehrlich, Ashley Bruno, et al.
Therapeutic Advances in Neurological Disorders|September 6, 2018
Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAINScott D Newsome, Thomas F Scott, Douglas L Arnold, et al.
Pageof 4